NCT01714115

Use of Eylea for the Treatment of an Optic Nerve Hemangioma

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Vitreous -Retina- Macula Consultants of New York · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: —

Summary

This is a single patient investigative treatment study. The patient was diagnosed with a retinal tumor in one eye. In the last 2 years, the patient has been treated with all available and conventional therapies, including intraocular injections of Avastin and Lucentis, steroids, and photodynamic therapy. Any positive results were short-term, and caused an eventual decline in central vision. Aflibercept has been shown to be effective against the growth of new vessels, secondary to macular degeneration. This study proposes that it may also be more effective in treating this particular patient and case. The study treatment plan is for 6 months initially, with the intention to continue treatment.

Detailed description

The treatment plan will be to administer aflibercept 2.0 mg intravitreally every two to four weeks for at least six consecutive injections. Prior to initiation of therapy and at each study visit, a full ophthalmic examination, best-corrected visual acuity, and a complete review of systems to monitor for any toxicity will be performed. In addition, the investigators will perform fluorescein and indocyanine green angiography at baseline and obtain color fundus photographs as well as spectral domain OCT images to properly document the extent and degree of activity of the vascular tumor at baseline and at all study visits.

Conditions

• Retinal Hemangioma

Interventions

Type	Name	Description
DRUG	Aflibercept	2.0 mg Intravitreal Injection, every 2 to 4 weeks

Timeline

• First posted: 2012-10-25
• Last updated: 2017-08-08

Locations

1 site across 1 country: United States